Targeting the Warburg Effect with the Glucose Mutation Theory: A Case Study of a 35-Year-Old Female Treated for Stage II Triple-Positive Metastatic Breast Cancer Involving Lymph Nodes Using Glucosodiene Over a 20-Day Period.

Abstract

Triple-positive breast cancer, characterized by the overexpression of estrogen receptors (ER+), progesterone receptors (PR+), and human epidermal growth factor receptor 2 (HER2+), poses a formidable challenge in oncology. This subtype, known for its aggressive nature and metastatic potential, requires a comprehensive therapeutic strategy. Current approaches, predominantly involving targeted therapies, face challenges, necessitating the exploration of alternative interventions. The emergence of Glucosodiene, rooted in Maher Akl's theory on glucose mutation, introduces a promising avenue for treatment. This innovative drug demonstrates efficacy in targeting the Warburg effect prevalent in tumors dependent on anaerobic glucose metabolism. A case study involving a 35-year-old woman with stage II triple-positive breast cancer showcases Glucosodiene's impact, revealing a complete absence of active lesions post-treatment. The results indicate its potential as a primary or secondary therapy, complementing traditional treatment protocols. Glucosodiene's mechanism of action positions it as a versatile and impactful option in the realm of cancer therapeutics, offering hope in the pursuit of improved patient outcomes. THE TRIAL IS REGISTERED UNDER CLINICALTRIALS.GOV NUMBER NCT05957939.